Refractory Cancer

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Individualized Treatments in Adults With Relapsed/Refractory Cancers

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

A Study of Avutometinib for People With Solid Tumor Cancers

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

Plan Development for Giving Teclistamab in the Outpatient Setting

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

9-ING-41 in Pediatric Patients With Refractory Malignancies.